Durata Therapeutics, Inc. Company Presentation

September 2012

Forward Looking Statements

1

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements contained in this presentation reflect Durata’s current views with respect to future events, and Durata assumes no obligation to update any forward-looking statements except as required by applicable law.

Durata Enterprise Development

Targeted indication development and

registration

Follow on indication/formulation development and life-

cycle management

Global commercialization with

select regional partnerships and

targeted acquisitions of commercial stage

products

Acquisition of novel clinical assets in

infectious disease targeted at acutely ill

patients

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. We are currently enrolling and dosing patients in two global Phase 3 clinical trials with our lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI.

2

20 years of experience in the pharmaceutical industry Former CFO of MedPointe Healthcare and multiple senior level finance and operations positions

The Durata Management Team

Paul Edick CEO

Corey Fishman COO/CFO

Michael Dunne MD CMO

John Shannon CCO

34 years of experience in the pharmaceutical industry Former CEO of MedPointe Healthcare, Group VP and President, Asia Pacific/Latin America at Pharmacia and President of Asia Pacific, Latin America and Canada for G.D. Searle

Over 19 years of experience in the pharmaceutical industry Former VP and Therapeutic Area Head for clinical development in Anti-Infectives at Pfizer MD at the State University of New York Health Sciences Center and ID fellowship at Yale

Over 25 years of experience in the pharmaceutical and healthcare industry Former GM of the Global Hemophilia Franchise and US Biopharm Business, VP Marketing for Biopharm NA and VP Marketing for the US Renal Business at Baxter

3

Primary Asset Highlights Dalbavancin is a highly differentiated, late stage, product candidate

A prior phase 3 program documented efficacy, safety and tolerability

Opportunities exist for expansion beyond the primary indication

Clearly defined clinical and regulatory path with FDA and EMA

New phase 3 studies at an advanced stage

Large and growing category

Value added health-economics

Worldwide development and commercial rights

Patent coverage / exclusivity through 2023

Highly experienced management team

4

Dalbavancin: Differentiation and Existing data

Dalbavancin is a semisynthetic glycopeptide (lipoglycopeptide) which interferes with peptidoglycan cross-linking in the cell wall by binding to the D-ala-D-ala terminus of stem peptides.

Dalbavancin: Mechanism of Action

*Streit, et al. DMID 2004, p137

Comparative MIC90 (µg/ml) of selected agents and dalbavancin tested against Worldwide clinical isolates (2002)*

S. aureus (1,815) OX-S

S. aureus (1,177) OX-R

β-hemolytic streptococci

(234)

viridans group streptococci

(30) PCN-R

Dalbavancin 0.06 0.06 0.06 0.03

Teicoplanin 1 2

Vancomycin 1 2 0.5 0.5

Oxacillin S R PCN = 0.06 R

Linezolid 2 2 1 1

6

Dalbavancin: Unique Pharmacokinetic Profile

Dalbavancin dosed with 1,000 mg IV on Day 1 and 500 mg IV on Day 8

Dorr, JAC 2005;55 Supp S2:ii25; data on file

Dalbavancin’s pharmacokinetic profile enables:

Broad tissue distribution

Continuous cidality

Once weekly dosing

Maintenance of high plasma concentration

7

Dalbavancin Existing Data – Efficacy in Multiple Completed Phase 3 Trials

Dalbavancin Was Shown to be as Effective as Three Different Agents in Respective Treatment Populations

VER001-8

VER001-9 Trial Description * Comparator Total Dosed

Dalbavancin Dosed

Treatment of complicated skin infections

Linezolid 854 571

Non-inferiority established

Non-inferiority established

Trial Description Comparator Total Dosed

Dalbavancin Dosed

Treatment of uncomplicated skin infection

Cefazolin 553 367

VER001-16

Non-inferiority established

Trial Description Comparator Total Dosed

Dalbavancin Dosed

Treatment of skin infections with suspected or confirmed methicillin resistant staphylococcus aureus (MRSA)

Vancomycin 156 107

* Luis E. Jauregui, et.al Clinical Infectious Diseases 2005; 41:1407–15

8

Adverse Events Occurring in >2% of Patients Receiving Dalbavancin: Phase 2/3 Integrated Database [Number (%) of Patients]

Preferred Term of Adverse Event

Total Dalbavancin (N = 1126)

Total Comparator (N = 573)

Patients with at least 1 Adverse Event

585 (52.0) 326 (56.9)

Nausea 69 (6.1) 47 (8.2) Diarrhea NOS 63 (5.6) 39 (6.8) Headache 54 (4.8) 33 (5.8) Constipation 40 (3.6) 29 (3.3) Vomiting NOS 40 (3.6) 26 (4.5) Urinary tract infection NOS 34 (3.0) 12 (2.1) Anemia NOS 31 (2.8) 12 (2.1) Rash NOS 29 (2.6) 13 (2.3) Pruritus 25 (2.2) 14 (2.4)

Dalbavancin: Demonstrated Low Level of Side Effects

The duration of adverse events on dalbavancin was no longer than that of comparators

Source: Durata Therapeutics, data on file

9

Dalbavancin: Potential Opportunities Beyond the abSSSI Indication

Dalbavancin in abSSSI Program to complete re-activated NDA will conclude in 4Q 2012 /1Q 2013

• Data in Bacteremia will be available as a sub-

analysis and for publication at time of launch

Dalbavancin in Osteomyelitis

Program to pursue a near term publication is underway Dalbavancin in Diabetic Foot Ulcer

Program to pursue a near term publication, probably with Phase 2 data, could result in publications available during year 1 of commercial sale

Dalbavancin in Hospitalized Community Acquired Pneumonia

Phase 1 to be initiated in 2013

Preclinical Phase 1 Phase 2 Phase 3 NDA

10

Regulatory and Clinical Activities

Recent Regulatory Interactions: US & EU

An NDA re-activation is possible using the old number

The non-clinical package is complete and no new studies are required

One new clinical trial & re-analysis of VER001-9 needed to complete the filing

Safety database believed to be sufficient for approval

DUR000-201 – Non-Interventional, observational, Phase 2 clinical trial part of filing

Applying for QIDP designation

End of Phase 2 Meeting

June 2010

Operational Meeting

April 25, 2012

PDUFA V

Special Protocol Agreement for DUR001-301 (September 2010)

Special Protocol Agreement for DUR001-302 (June 2011)

EMA Scientific Advice

December 2010

Previously submitted package supports the claim

DISCOVER program with separate EU statistical analysis plan will be adequate

Durata decision to conduct two new Phase 3 studies to strengthen regulatory filing

12

NDA Timing

MAA Timing

Regulatory Filing Timing

2011 2012 2013 2014

3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q/2Q

Pre-NDA Meeting(s)

Phase 3 studies

Submission Preparation

Filing

Review/AC/Approval

2011 2012 2013 2014

3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q

Phase 3 studies

Submission Preparation

Scientific Adv./Rapporteurs

Filing

Review/Defense/Approval

13

Market Opportunity

Dalbavancin Commercial Thesis Large U.S. abSSSI (at risk for MRSA) market; 35mm Days Of Therapy (DOT), dominated by generic vancomycin

High and growing prevalence of MRSA leads to empiric selection of therapies

Providers respond favorably to the Dalbavancin product profile

Dalbavancin profile represents opportunity to move patients to ambulatory or outpatient care

Dalbavancin profile is very attractive in indications beyond abSSSI

Reimbursement metrics driving care to hospital ambulatory or out-patient clinics

Reduction in total treatment cost is a major driver of adoption

Customer universe is highly targeted

Source: LEK analysis and interviews

15

U.S. Market Opportunity We believe there are ~35 million days of treatment (DOT) annually, in the U.S.,

for abSSSI patients at risk for MRSA utilizing intravenous antibiotics; this represents a market potential of approximately $10 billion at branded pricing *

Product DOT (millions)

Vancomycin 7.2

Cefazolin 3.4

Piperacillin 3.4

Clindamycin 2.5

Ampicillin 1.6

Ceftriaxone 1.3

Levofloxacin 1.1

Gentamicin 0.7

Daptomycin 0.6

Tigecycline 0.4

Leading Products

Market is larger when expanded to include MSSA and oral step-down therapies

* If generic units were converted to branded daptomycin pricing Source: Stanford Group June 2007, AMR 2010

16

Clinician Response to Dalbavancin Product Profile

1 2 3 4 5 6 7 8 9 10

Hosp ER ID

1% 0% 0% 1% 3%

7%

20%

31%

20% 18%

“Very Poor” “Excellent”

• Mean response = 8.1

• 69% responded 8 or higher

• <2% responded below 5

• Responses consistent across ER docs, ID docs and hospitalists

ePocrates market research, May 2009, 150 physicians

17

1 = Not favorable at all; 10 = Extremely favorable

8.9

8.7

8.7

8.7

8.5

8.3

8.1

6.2

Ensured compliance for 7 days

Potential to reduce in-patient stay

Dose regime (day 1 & 8)

No need for PICC line

No blood monitoring

Bactericidal activity

Safety / tolerability profile

Glycopeptide class

Clinician Response to Dalbavancin Product Profile by Feature

ePocrates market research, May 2009, 150 physicians

18

Clinicians Response to Treatment Setting Using Dalbavancin 86% of respondents believe that >10% of SSSI patients, currently admitted to the hospital, could be treated as an outpatient with dalbavancin

1%

2%

11%

25%

22%

24%

15%

0

1-5%

6-10%

11-20%

21-30%

31-50%

>50%

Institutional burden is a factor for assessing benefit

Q: What percent of SSSI patients currently admitted to the hospital could now be treated on an outpatient basis over the entire course of treatment due to this product’s profile?

Q: Will your hospital/institution factor in the savings from administrative benefits, such as lower burden on nursing time, in assessing the cost/benefit of this drug?

Yes82%

No18%

ePocrates market research, May 2009, 150 physicians

19

Customer Insight

We have continued to collect informal customer feedback from selected stakeholders:

Homecare, Urgent care, PBMs

ER management companies & Hospital systems

Large infectious disease practices

Clinical pharmacy at major institutions

High control payors

Themes Awareness of dalbavancin

Dalbavancin potential to impact OPAT

Ambulatory administration & resulting economics are a potential advantage

20

Financial Penalties are Driving Hospitals to Deliver Care in Ambulatory or Out-patient Settings

Hospital Acquired Conditions (HACs) Hospital Readmissions ****

Financial penalties for conditions that patients acquire during a hospital stay

Medicare - Hospitals in the top quartile for HACs will receive a 1% decrease in DRG payments*

Medicaid - Secretary of HHS adopts regulations prohibiting federal payments for HACs***

Secretary of HHS to publicize information on HAC rates

Medicaid prohibition – FY 2011***

Medicare reductions – FY 2014**

Financial penalties for avoidable hospital readmissions

Hospitals will have payments reduced by 1% in 2013 and increasing to 3% by 2015

Hospitals required to submit data to either the Secretary of HHS or to the States to determine patient readmission rates

Secretary of HHS to publicize information on readmission rates

Begins FY 2013

*The Deficit Reduction Act of 2005, Pub. L. No. 109-171, sec. 5001(c), "Quality Adjustment in DRG Payments for Certain Hospital Acquired Infections“ **The Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-148, sec. 3008, "Payment Adjustment for Conditions Acquired in Hospitals" ***The Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-148, sec. 2702, "Payment Adjustment for Health Care-Acquired Conditions" ****PPACA The Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-148, sec. 3025, "Hospital Readmissions Reduction Program"

21

Reduction in Total Treatment Costs are Expected to Drive Adoption

Decreased length of stay

Potential admission avoidance

Less indwelling catheters

No therapeutic drug monitoring

Less ancillary supply utilization

Shorter nursing time

Lower drug preparation frequency

Less drug wastage

Red

uced

Impr

oved

Improved patient convenience, compliance, and satisfaction

22

Outpatient infusion codes are more common in HOPD with only 1-3 physician (E/M) services billed per course of therapy

Source: Avalere Health LLC analysis of 2010 Medicare Standard Analytic Files (SAFs)

Daptomycin Length of therapy Physician

Office 10.88 days

HOPD 8.56 days

Frequency of Physician E/M Billing per Therapy Course

Hypothetical Early Intervention Scenario with Dalbavancin and Potential Cost Implications1

1. Jauregui, et al. Clin. Infect. Dis. 2005;41:1407-1415

Scenario 1: Assumes 1st line

treatment only, equal efficacy 88.9%2

Comparators and Selected Assumptions:

1) Dalbavancin: 3 days inpatient 11 days outpatient

2) Vancomycin: 3 days inpatient 11 days outpatient

3) Daptomycin: 3 days inpatient 11 days outpatient

24

Scenario : Assumes 1st line treatment only, equal efficacy 88.9%1

Comparators and Selected Assumptions:

1) Dalbavancin: 14 days outpatient (no inpatient admission)

2) Vancomycin: 3 days inpatient

+ Linezolid (oral): 11 days outpatient

3) Daptomycin: 3 days inpatient, 11 days outpatient

1. Jauregui, et al. Clin. Infect. Dis. 2005;41:1407-1415

Hypothetical Early Intervention Scenario with Dalbavancin and Potential Cost Implications

25

Commercial Plan Requires Modest Investment

In the US, approximately 2,000 hospitals/ambulatory centers account for a large percentage of the market opportunity

Pre-Launch efforts will focus on key stakeholders:

− Mapping formulary submission processes and evidence requirements

− Development and validation of value dossier, formulary submissions

− Infectious disease and pharmacy -- key thought leader development

− Develop key account plans and value proposition with payers and hospital administration

− Develop reimbursement support services and resources

Target audiences:

− 1,600-2,000 Hospitals

− 7,000 IDs

− 6,000 high volume (gram + utilization) IMs and surgeons

Anticipate a commercial organization of ~140, including hospital specialists, key accounts, formulary, marketing and reimbursement support

Similar characteristics typify the EU5 marketplace

26

Intellectual Property/Exclusivity

Timeline of Dalbavancin Protection Dalbavancin patents/exclusivity provide protection until 2023

Dalbavancin’s patent strength emanates from covering a wide range of dosing intervals, dosages, and the amount of dalbavancin in each dose:

Administering initial and subsequent therapeutically effective doses wherein: − Each dose is separated by 5 -10 days − Amount of each dose is about 100mg to 5,000mg − Amount of initial dose is at least about two times the amount of the subsequent dose

2005 2010 2020 2025 2030 2015

United States

Europe

Once-Weekly Patent (USP 6,900,175) Potential Patent Term Extension

EP 0 596 929 EP Data Exclusivity

Pediatric Extension Potential GAIN

Exclusivity Extension US Data Exclusivity

28

Durata Summary

Primary Asset Highlights

30

Dalbavancin is a highly differentiated, late stage, product candidate

A prior phase 3 program documented efficacy, safety and tolerability

Potential opportunities exist for expansion beyond the primary indication

Clearly defined clinical and regulatory path with FDA and EMA

New phase 3 studies at an advanced stage

Large and growing category

Value added health-economics

Worldwide development and commercial rights

Patent coverage / exclusivity through 2023

Highly experienced management team

Durata Therapeutics